List view / Grid view
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
A new study reveals a promising approach to sepsis treatment by targeting the VHR enzyme using fragment-based drug discovery. This innovative method could lead to more effective therapies for sepsis and other immune-related conditions.
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
21 March 2025 | By Abzena
Join our webinar with Abzena’s experts to explore practical solutions for overcoming chemistry, manufacturing and regulatory challenges in antibody-oligonucleotide conjugate (AOC) development, enabling progress for previously untreatable diseases.
Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
A recent study led by Dr Richard McNair highlights the role of the Marangoni effect in surfactant spreading, offering potential improvements in drug development and delivery for lung diseases.
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments.
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
York University researchers have discovered a genetic mutation in the TRAF1 protein that dramatically reduces inflammation, offering a potential breakthrough in rheumatoid arthritis treatment.
